National Healthcare Properties, Inc.
National Healthcare Properties Reports Third Quarter 2026 Results
SHOP Same Store Cash NOI increased 13.6% year-over-year —
Source
From GlobeNewswire
29 releases originally issued via GlobeNewswire. The issuing organizations are responsible for their content.
Pacific Biosciences Of California, Inc.
PacBio Announces Third Quarter 2026 Financial Results
Arq, Inc.
Arq Reports Third Quarter 2026 Results
Achieved record quarterly revenue of $38.2 million (+9% YoY) and Net income of $2.5 million
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Progyny, Inc.
Progyny, Inc. Announces Third Quarter 2026 Results
Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net Income
Carriage Services Inc
CARRIAGE SERVICES INC
Carriage Services Announces Third Quarter 2026 Results, Updates 2026 Guidance
electroCore, Inc.
electroCore Announces Third Quarter 2026 Financial Results
Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025
Cytek Biosciences, Inc.
Cytek Biosciences Reports Third Quarter 2026 Financial Results
TWFG, Inc.
TWFG Announces Third Quarter 2026 Results
– Total Revenues increased 24.6% for the quarter over the prior year period to $79.9 million –
Pennant Group, Inc.
Pennant Reports Third Quarter 2026 Results
Conference Call and Webcast scheduled for tomorrow, November 5, 2026 at 10:00 am MT
Twin Disc Inc
Twin Disc Announces First Quarter Results
Riot Platforms, Inc.
Riot Platforms Reports Third Quarter 2026 Financial Results and Strategic Highlights
Executed a 15-year, 910 critical IT MW triple-net powered land lease with a leading Frontier AI Lab at Corsicana, representing approximately $28…
Geron Corp
Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Achieved $60.1 million in RYTELO® (imetelstat) net product revenue in Q3 2026, an increase of 5% compared to Q2 2026
Odyssey Therapeutics, Inc.
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis
Biocryst Pharmaceuticals Inc
BioCryst Reports Third Quarter 2026 Financial Results
Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million —
Rapport Therapeutics, Inc.
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027
Ridgepost Capital, Inc.